Senseonics (NYSE:SENS) announced today that the FDA approved its next-generation continuous glucose monitor system, which lasts up to half a year.
Germantown, Maryland–based Senseonics designed the Eversense E3, which includes proprietary sacrificial boronic acid (SBA) technology, to extend longevity to six months (180 days). Senseonics previously offered the system with a 90-day wear time.
Data presented in 2021 showed strong accuracy with the fully implantable, 180-day sensor. The next-generation platform matched performance levels compared to the 90-day version, but with calibration reduced to essentially once per day. One of the sensor’s tests produced a mean absolute relative difference (MARD) of 8.5%, representing high accuracy
Get the full story at our sister site, Drug Delivery Business News.